Actively Recruiting
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
Led by Fudan University · Updated on 2025-08-26
545
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study from Eastern Cooperative Thoracic Oncology Project, numbered as ECTOP-1009. Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a multi-center, prospective clinical trial
CONDITIONS
Official Title
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical stage T1N0M0 and planned curative surgery
- A single lesion detected on computed tomography (CT) scan featured as ground glass nodule (GGO) with consolidation-to-tumor (C/T) ratio 60.5
- Age 18 to 75 years
- Patients who have signed the informed consent form
You will not qualify if you...
- Other than invasive adenocarcinoma by pathological analysis
- Patients undergoing wedge resection but not meeting the specific conditions of consolidation/tumor ratio 60.25 and maximum tumor diameter 62 cm
- Not completely resected or without curative intent
- History of other malignant tumors
- History of thoracic surgery
- Previous radiation, chemotherapy, or other treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
Research Team
H
Haoxuan Wu, Dr.
CONTACT
H
Haiquan Chen, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here